- Home
- ALLO vs YDES Comparison
ALLO vs YDES Comparison
Compare ALLO & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | YDES |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 476.8M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ALLO | YDES |
|---|---|---|
| Price | $1.22 | $4.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 369.9K |
| Earning Date | 11-05-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $255.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $1.70 |
| 52 Week High | $4.46 | $18.57 |
Technical Indicators
Market Signals| Indicator | ALLO | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 39.75 |
| Support Level | N/A | $2.33 |
| Resistance Level | $2.22 | $5.15 |
| Average True Range (ATR) | 0.08 | 1.00 |
| MACD | -0.00 | -0.29 |
| Stochastic Oscillator | 0.00 | 0.59 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.